• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience.

作者信息

Riccio Eleonora, Amicone Maria, Capuano Ivana, Pacella Daniela, Pisani Antonio

机构信息

Chair of Nephrology, Department of Public Health, Federico II University, Naples, Italy.

Department of Public Health, Federico II University, Naples, Italy.

出版信息

J Nephrol. 2024 Dec;37(9):2683-2685. doi: 10.1007/s40620-024-02145-w. Epub 2024 Nov 6.

DOI:10.1007/s40620-024-02145-w
PMID:39503964
Abstract
摘要

相似文献

1
Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience.奥曲肽长效释放制剂用于肾功能极低的常染色体显性多囊肾病患者：单中心真实世界经验
J Nephrol. 2024 Dec;37(9):2683-2685. doi: 10.1007/s40620-024-02145-w. Epub 2024 Nov 6.
2
Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.常染色体显性多囊肾病中左心室功能障碍和奥曲肽长效释放剂的作用：ALADIN 试验的横断面和纵向亚研究。
Int J Cardiol. 2019 Jan 15;275:145-151. doi: 10.1016/j.ijcard.2018.10.063. Epub 2018 Oct 22.
3
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.奥曲肽长效释放剂治疗晚期常染色体显性遗传多囊肾病（ALADIN 2）：一项随机、双盲、安慰剂对照、多中心试验。
PLoS Med. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777. eCollection 2019 Apr.
4
Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial.奥曲肽长效释放制剂联合托伐普坦治疗常染色体显性遗传多囊肾病的效果：一项先导、随机、安慰剂对照、交叉试验。
Clin J Am Soc Nephrol. 2023 Feb 1;18(2):223-233. doi: 10.2215/CJN.0000000000000049.
5
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.长效生长抑素类似物对常染色体显性多囊肾病（ALADIN）患者肾脏和囊肿生长的影响：一项随机、安慰剂对照、多中心试验。
Lancet. 2013 Nov 2;382(9903):1485-95. doi: 10.1016/S0140-6736(13)61407-5. Epub 2013 Aug 21.
6
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.奥曲肽对多囊肾病和肝病患者肝体积的长期影响。
Clin Gastroenterol Hepatol. 2016 Jul;14(7):1022-1030.e4. doi: 10.1016/j.cgh.2015.12.049. Epub 2016 Feb 1.
7
Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan.日本生长抑素类似物奥曲肽用于常染色体显性多囊肾病的安全性研究。
Clin Exp Nephrol. 2015 Aug;19(4):746-52. doi: 10.1007/s10157-014-1047-1. Epub 2014 Oct 29.
8
Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature.托伐普坦与生长抑素治疗 ADPKD：文献复习。
Clin Nephrol. 2022 Mar;97(3):131-140. doi: 10.5414/CN110510.
9
[ADPKD treatment: Tolvaptan and Octreotide].[常染色体显性多囊肾病的治疗：托伐普坦和奥曲肽]
G Ital Nefrol. 2019 Dec 9;36(6):2019-vol6.
10
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.长作用生长抑素治疗常染色体显性遗传多囊肾病和多囊肝病的随机临床试验。
J Am Soc Nephrol. 2010 Jun;21(6):1052-61. doi: 10.1681/ASN.2009121291. Epub 2010 Apr 29.

本文引用的文献

1
Glomerular hyperfiltration.肾小球高滤过。
Nat Rev Nephrol. 2022 Jul;18(7):435-451. doi: 10.1038/s41581-022-00559-y. Epub 2022 Apr 1.
2
The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials.生长抑素类似物对多囊肝病患者肝体积和生活质量的影响：一项随机对照试验的荟萃分析。
Sci Rep. 2021 Dec 6;11(1):23500. doi: 10.1038/s41598-021-02812-z.
3
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
奥曲肽长效释放剂治疗晚期常染色体显性遗传多囊肾病（ALADIN 2）：一项随机、双盲、安慰剂对照、多中心试验。
PLoS Med. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777. eCollection 2019 Apr.
4
Autosomal dominant polycystic kidney disease.常染色体显性遗传性多囊肾病。
Lancet. 2019 Mar 2;393(10174):919-935. doi: 10.1016/S0140-6736(18)32782-X. Epub 2019 Feb 25.
5
Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.常染色体显性多囊肾病中左心室功能障碍和奥曲肽长效释放剂的作用：ALADIN 试验的横断面和纵向亚研究。
Int J Cardiol. 2019 Jan 15;275:145-151. doi: 10.1016/j.ijcard.2018.10.063. Epub 2018 Oct 22.
6
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.长效生长抑素类似物对常染色体显性多囊肾病（ALADIN）患者肾脏和囊肿生长的影响：一项随机、安慰剂对照、多中心试验。
Lancet. 2013 Nov 2;382(9903):1485-95. doi: 10.1016/S0140-6736(13)61407-5. Epub 2013 Aug 21.
7
Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease.常染色体显性遗传性多囊肾病患儿的肾小球高滤过和肾脏进展。
Clin J Am Soc Nephrol. 2011 Oct;6(10):2439-43. doi: 10.2215/CJN.01010211. Epub 2011 Sep 8.